Orion Oyj (OTCMKTS:ORINY) Reaches New 1-Year High – Time to Buy?

Orion Oyj (OTCMKTS:ORINY)’s stock price hit a new 52-week high on Monday . The company traded as high as $28.63 and last traded at $28.63, with a volume of 946 shares trading hands. The stock had previously closed at $28.14.

Analyst Upgrades and Downgrades

Separately, Nordea Equity Research lowered Orion Oyj to a “hold” rating in a research note on Tuesday, February 4th.

Orion Oyj Stock Up 1.7 %

The stock has a market capitalization of $8.08 billion, a P/E ratio of 22.72 and a beta of 0.25. The firm’s fifty day moving average is $25.06 and its 200-day moving average is $25.19. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25.

Orion Oyj (OTCMKTS:ORINY) last posted its earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. The company had revenue of $463.41 million during the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. As a group, equities research analysts predict that Orion Oyj will post 1.18 earnings per share for the current year.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.